{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:10:46Z","timestamp":1777900246170,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["AI123337"],"award-info":[{"award-number":["AI123337"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.anai.2023.01.024","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T21:32:02Z","timestamp":1675287122000},"page":"617-621.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Further evidence of a type 2 inflammatory signature in chronic obstructive pulmonary disease or emphysema"],"prefix":"10.1016","volume":"130","author":[{"given":"Larry","family":"Borish","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Gerald","family":"Teague","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James T.","family":"Patrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin W.","family":"Wavell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Barros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Charles","family":"Malpass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6450-3182","authenticated-orcid":false,"given":"Monica G.","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.anai.2023.01.024_bib0001","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.jaip.2019.01.036","article-title":"T2 biologics for chronic obstructive pulmonary disease","volume":"7","author":"Yousuf","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"9240","key":"10.1016\/j.anai.2023.01.024_bib0002","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S0140-6736(00)02872-5","article-title":"Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial","volume":"356","author":"Brightling","year":"2000","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.anai.2023.01.024_bib0003","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2023.01.024_bib0004","first-page":"39","article-title":"Eosinophilic airway inflammation in COPD","volume":"1","author":"Saha","year":"2006","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"3","key":"10.1016\/j.anai.2023.01.024_bib0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/thx.2004.032516","article-title":"Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease","volume":"60","author":"Brightling","year":"2005","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.anai.2023.01.024_bib0006","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/09031936.00162414","article-title":"Eosinophilic inflammation in COPD: prevalence and clinical characteristics","volume":"44","author":"Singh","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2023.01.024_bib0007","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2147\/COPD.S100338","article-title":"Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD","volume":"11","author":"Negewo","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.anai.2023.01.024_bib0008","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12931-019-1111-1","article-title":"Do blood eosinophils strictly reflect airway inflammation in COPD? Comparison with asthmatic patients","volume":"20","author":"Pignatti","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.anai.2023.01.024_bib0009","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.2147\/COPD.S294333","article-title":"Mepolizumab for eosinophil-associated COPD: analysis of METREX and METREO","volume":"16","author":"Pavord","year":"2021","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"10.1016\/j.anai.2023.01.024_bib0010","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/all.14661","article-title":"Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease","volume":"76","author":"Higham","year":"2021","journal-title":"Allergy"},{"issue":"7","key":"10.1016\/j.anai.2023.01.024_bib0011","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1164\/rccm.201408-1458OC","article-title":"Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease","volume":"191","author":"Christenson","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.anai.2023.01.024_bib0012","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/all.14741","article-title":"Molecular markers of type 2 airway inflammation are similar between eosinophilic severe asthma and eosinophilic chronic obstructive pulmonary disease","volume":"76","author":"Fricker","year":"2021","journal-title":"Allergy"},{"issue":"Suppl 2","key":"10.1016\/j.anai.2023.01.024_bib0013","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1590\/S0074-02761997000800012","article-title":"IL-5 and IL-5 receptor in asthma","volume":"92","author":"Kotsimbos","year":"1997","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"5","key":"10.1016\/j.anai.2023.01.024_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.04.025","article-title":"Human group 2 innate lymphoid cells do not express the IL-5 receptor","volume":"140","author":"Wright","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2023.01.024_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2021.08.004","article-title":"Interleukin-5 receptor alpha (CD125) expression on human blood and lung neutrophils","volume":"128","author":"Lawrence","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.anai.2023.01.024_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0221113","article-title":"Expression of IL-5 receptor alpha by murine and human lung neutrophils","volume":"14","author":"Gorski","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.anai.2023.01.024_bib0017","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1172\/JCI85664","article-title":"Lung-resident eosinophils represent a distinct regulatory eosinophil subset","volume":"126","author":"Mesnil","year":"2016","journal-title":"J Clin Invest"},{"issue":"1-2","key":"10.1016\/j.anai.2023.01.024_bib0018","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.vetimm.2005.06.017","article-title":"Expression of interleukin (IL)-5 and IL-9 receptors on neutrophils of horses with heaves","volume":"109","author":"Dewachi","year":"2006","journal-title":"Vet Immunol Immunopathol"},{"issue":"7","key":"10.1016\/j.anai.2023.01.024_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002365","article-title":"IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: a reverse translation study from a human cohort to a mouse trauma model","volume":"14","author":"Xu","year":"2017","journal-title":"PloS Med"},{"issue":"7","key":"10.1016\/j.anai.2023.01.024_bib0020","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1182\/blood-2003-04-1078","article-title":"Toll-like receptors stimulate human neutrophil function","volume":"102","author":"Hayashi","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.anai.2023.01.024_bib0021","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1164\/rccm.201201-0134OC","article-title":"Interleukin 5 is protective during sepsis in an eosinophil-independent manner","volume":"186","author":"Linch","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2023.01.024_bib0022","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12931-020-01544-4","article-title":"Exploration of the sputum methylome and omics deconvolution by quadratic programming in molecular profiling of asthma and COPD: the road to sputum omics 2.0","volume":"21","author":"Groth","year":"2020","journal-title":"Respir Res"},{"key":"10.1016\/j.anai.2023.01.024_bib0023","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front Physiol"},{"issue":"6","key":"10.1016\/j.anai.2023.01.024_bib0024","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1183\/09031936.04.00014304","article-title":"Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS\/ERS position paper","volume":"23","author":"Celli","year":"2004","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.anai.2023.01.024_bib0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1440-1843.2006.00784.x","article-title":"Inflammatory subtypes in asthma:assessment and identification using induced sputum","volume":"11","author":"Simpson","year":"2006","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.anai.2023.01.024_bib0026","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.00.15121700","article-title":"Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children","volume":"15","author":"de Blic","year":"2000","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2023.01.024_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.04.027","article-title":"Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts","volume":"140","author":"Kolsum","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2023.01.024_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2018.12.027","article-title":"Lung lavage granulocyte patterns and clinical phenotypes in children with severe, therapy-resistant asthma","volume":"7","author":"Teague","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2023.01.024_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2013.09.035","article-title":"CD49d-expressing neutrophils differentiate atopic from nonatopic individuals","volume":"133","author":"Sigua","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.anai.2023.01.024_bib0030","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1046\/j.1365-2222.2003.01786.x","article-title":"Expression of cysteinyl leukotriene synthetic and signalling proteins in inflammatory cells in active seasonal allergic rhinitis","volume":"33","author":"Figueroa","year":"2003","journal-title":"Clin Exp Allergy"},{"issue":"12","key":"10.1016\/j.anai.2023.01.024_bib0031","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2213-2600(17)30432-0","article-title":"Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort","volume":"5","author":"Hastie","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.anai.2023.01.024_bib0032","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.4049\/jimmunol.169.11.6459","article-title":"Decreased expression of membrane IL-5 receptor alpha on human eosinophils: II. IL-5 down-modulates its receptor via a proteinase-mediated process","volume":"169","author":"Liu","year":"2002","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.anai.2023.01.024_bib0033","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/0091-6749(89)90115-2","article-title":"Interleukin-4 is a neutrophil activator","volume":"83","author":"Boey","year":"1989","journal-title":"J Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623000789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120623000789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:32:11Z","timestamp":1761053531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120623000789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1081120623000789"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2023.01.024","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Further evidence of a type 2 inflammatory signature in chronic obstructive pulmonary disease or emphysema","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2023.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}